EVIDENTIARY CRITERIA FOR ACCELERATED APPROVAL OF NEW MEDICINES: CATALOGING FDA'S FLEXIBILITY IN SUBPART H APPROVALS

Sasinowski F.; Varond A.

首页> 外文期刊>Muscle and Nerve >EVIDENTIARY CRITERIA FOR ACCELERATED APPROVAL OF NEW MEDICINES: CATALOGING FDA'S FLEXIBILITY IN SUBPART H APPROVALS

【24h】

EVIDENTIARY CRITERIA FOR ACCELERATED APPROVAL OF NEW MEDICINES: CATALOGING FDA'S FLEXIBILITY IN SUBPART H APPROVALS

机译：加速批准新药的证据标准：FDA在SUBPHART H批准中的灵活性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Muscle and Nerve》 |2014年第s1期|共2页
作者
Sasinowski F.; Varond A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类人体生理学;
关键词

相似文献

外文文献
中文文献
专利

1. EVIDENTIARY CRITERIA FOR ACCELERATED APPROVAL OF NEW MEDICINES: CATALOGING FDA'S FLEXIBILITY IN SUBPART H APPROVALS [J] . Sasinowski F., Varond A. Muscle and Nerve . 2014,第S1期

机译：加速批准新药的证据标准：FDA在SUBPHART H批准中的灵活性
2. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations (vol 21, pg 542, 2019) [J] . Issa Amalia M., Thorogood Adrian, Joly Yann, Genetics in medicine . 2019,第8期

机译：加速证据收集和批准精确医学疗法：FDA瞄准罕见突变（第21卷，PG 542,2019）
3. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations [J] . Issa Amalia M., Thorogood Adrian, Joly Yann, Genetics in medicine . 2019,第3期

机译：加速证据收集和批准精确医学疗法：FDA瞄准罕见突变
4. The travail involved in getting FDA approval . . . an overview on what it took to get FDA approval of a medical device with computer technology (A recent experience) [C] . Paul, A. Engineering of Computer-Based Medical Systems, 1988., Proceedings of the Symposium on the . 1988

机译：这次灾难涉及获得FDA批准。。。 FDA批准使用计算机技术的医疗设备所需的概述（最近的经验）
5. Evidence Supporting FDA Approval and CMS National Coverage Determinations for Novel Medical Products, 2005 through 2016: A Cross-Sectional Study [D] . Roginiel, Aliya C. 2019

机译：证据支持FDA批准和CMS全国新型医疗产品的覆盖范围，2005年至2016年：横断面研究
6. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations [O] . Amalia M. Issa, Adrian Thorogood, Yann Joly, -1

机译：加快精确医学疗法的证据收集和批准：FDA瞄准罕见突变
7. Correction to: Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations [O] . Amalia M. Issa, Adrian Thorogood, Yann Joly, 2018

机译：纠正：加速证据收集和批准精确医学疗法：FDA瞄准罕见突变

EVIDENTIARY CRITERIA FOR ACCELERATED APPROVAL OF NEW MEDICINES: CATALOGING FDA'S FLEXIBILITY IN SUBPART H APPROVALS

著录项

相似文献

相关主题

期刊订阅